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Abstract 
Annexin II is a Ca2÷-regulated membrane- and cytoskeleton-binding protein implicated in membrane transport events along the 
Ca2+-regulated secretory and the early endocytic pathway. Biochemical properties of this annexin and its intracellular distribution are 
regulated by complex formation with p l 1 (S 100AI0), a member of the S 100 protein family. The annexin II-pl 1 interaction is mediated 
through the unique N-terminal domain of annexin II and is inhibited by protein kinase C phosphorylation f a serine residue in annexin II. 
To map this regulatory serine phosphorylation site we developed a baculovirus-mediated expression system for wild-type annexin II and 
for a series of annexin II mutants which contained substitutions in one or more serine residues present in the N-terminal domain. The 
different mutant derivatives were purified and shown to display the same biochemical properties as recombinant wild-type annexin II and 
the authentic protein purified fi'om porcine intestine. However, significant differences in phosphate incorporation were observed when the 
individual serine mutants were subjected to phosphorylation byprotein kinase C. A comparison of the phosphorylation patterns obtained 
identified Ser-11 as the protein kinase C site responsible for regulating the annexin II-pl 1 interaction. Ser-11 lies within the sequence 
mediating pl 1 binding, i.e. amino-acid residues 1 to 14 of annexin II, and phosphorylation at this site most likely leads to a direct spatial 
interference with pl 1 binding. 
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1. Introduction 
Annexins are a family of soluble proteins which interact 
with cellular membranes in a Ca 2 +-dependent manner (for 
review see [1-3]). They are widely expressed in animals 
and plants and are often found on or in close proximity to 
cellular membranes. Based on this intracellular localization 
and due to their typical biochemical properties annexins 
have been implicated in a number of membrane related 
events. These range from the establishment and/or  regula- 
tion of membrane-membrane dmembrane-cytoskeleton 
contacts to the organization of membrane domains and the 
regulation of ion currents across membranes (for review 
see [1-5]). 
Ca2+/phospholipid binding, the biochemical hallmark 
of the annexin family, is mediated through a protein core 
domain defined by its resistance towards limited proteoly- 
sis. This protein core is the principle structure of an 
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annexin and is built of four or eight repetitive segments of 
70 to 80 amino acids, the annexin repeats. So-called type 
II and type III Ca 2+ binding sites, which are different in 
architecture from the type I EF-hand motif, are present in 
the annexin cores and Ca 2+ bound to the type II site is 
thought o provide bridging between the protein and phos- 
pholipids in membrane-bound annexins [6-8]. Biochemical 
and functional specificity for a given annexin is thought o 
be conferred through an unique N-terminal domain, which 
is sensitive to mild proteolytic attack and precedes the 
C-terminal protein core. The N-terminal domains of the 
annexins also appear to be of regulatory importance as 
they often contain phosphorylation sites for signal trans- 
ducing kinases (for review see [2]). 
Annexin II is a substrate for serine/threonine- as well 
as tyrosine-specific kinases. All phosphorylation sites 
mapped so far are found in the N-terminal domain which 
as defined by limited chymotryptic leavage contains the 
first 29 residues (for review see [9]). Tyr-23 is phosphory- 
lated by the src tyrosine kinase [10] and by the insulin 
receptor kinase [11]. Ser-25, on the other hand, is a site for 
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phosphorylation by protein kinase C (PKC) [12,13]. The 
N-terminal domain of annexin II also harbours the binding 
site for a cellular protein ligand, pl 1, which is a member 
of the S100 family of dimeric EF-hand type Ca 2+ binding 
proteins (for review see [14]). Within the annexin II 
molecule the pl 1 binding site is contained in the N-termi- 
nal 14 residues and binding leads to the formation of a 
heterotetrameric annexin II2-pl 12 complex [15,16]. 
Both, p l l  binding and phosphorylation are of regula- 
tory importance with respect o the biochemical properties 
displayed by annexin II and are also thought o regulate 
the intracellular function of this annexin. Tyrosine-phos- 
phorylated annexin II has a reduced affinity towards 
Ca2+/phospholipid and phosphorylation at Ser-25 
markedly increases the Ca 2+ concentration required for 
phospholipid vesicle aggregation by the annexin II-pl 1 
complex [17,18]. Moreover, Ser-25 phosphorylation by 
PKC appears to be a prerequisite for the stimulation of 
Ca2+-dependent secretion by the annexin II-pl 1 complex 
observed in permeabilized chromaffin cells [19]. The Ca 2+ 
requirement for the annexin II-phospholipid interaction is 
altered by p l l  binding, since phospholipid binding and 
vesicle aggregation occur at significantly lower Ca z+ con- 
centrations in the case of the annexin II-pl 1 heterotetramer 
[17,20]. pl 1-induced formation of the annexin II-pl 1 com- 
plex also regulates the intracellular localization of annexin 
II. While monomeric annexin II is at least in part a 
cytosolic protein the annexin II-p 11 complex appears to be 
restricted to the membrane-associated cytoskeleton [21,22]. 
Here, the complex is thought o fulfill a structural role in 
linking peripheral membranes - e.g., secretory granules in 
chromaffin cells and early endosomes in differentiated 
epithelial cells - to one another and/or to the plasma 
membrane or the cortical cytoskeleton [23,24]. 
The complex formation between annexin II and p l l  
itself is also regulated through phosphorylation, since 
PKC-phosphorylated annexin II fails to bind pl 1 [13]. This 
regulatory important phosphorylation of annexin II by 
PKC occurs at a second serine residue in the N-terminal 
domain, which is different from Ser-25 and most likely 
also the target for calmodulin and cAMP-dependent ki- 
nases ['13]. Here we employed a mutagenesis approach 
combined with the in vitro phosphorylation f recombinant 
annexin II mutants expressed in baculovirus-infected insect 
cells to map this second PKC phosphorylation site. This 
approach unambiguously identifies Ser-ll located within 
the p l l  binding region and thus provides a structural 
explanation for the regulation of the annexin II-pl 1 inter- 
action through PKC phosphorylation. 
2. Material and methods 
2.1. Purification of porcine annexin H and p l l  
The heterotetrameric annexin II-pl 1 complex was iso- 
lated from porcine intestinal epithelium and dissociated 
into the annexin II and pl 1 subunits in the presence of 9 M 
urea [15]. The subunits were separated by gel filtration and 
then individually renatured by dialysis against 25 mM 
Tris-HC1 (pH 7.5), 100 mM NaC1, 3 mM MgCI 2, and 1 
mM NaN 3. 
2.2. Site-specific mutagenesis 
Specific mutations were introduced into the human 
annexin II cDNA [25] cloned into M13 mpl8 by oligo- 
nucleotide-directed mutagenesis [26]. Multiple mutations 
were introduced by annealing several oligonucleotides si-
multaneously. All mutations were verified by dideoxy 
sequencing [27]. Cloning was carried out following stan- 
dard procedures [28]. 
2.3. Construction of recombinant baculovirus clones 
Wild-type and mutant annexin II cDNA's were cloned 
into the BamHI/XbaI-linearized baculovirus transfer vec- 
tor pVL1393 [29]. Recombinant baculoviruses were pro- 
duced by homologous recombination following cotransfec- 
tion of 2 × 10 6 SF9 insect cells with 0.5 /xg baculo-gold 
DNA (Pharmingen) and 2 /zg of the respective pVL-Anx 
II plasmid DNA using 30 /zl lipofectin (Gibco BRL). The 
SF9 cells were cultivated for 5-7 days before the culture 
supernatant containing the recombinant baculoviruses was 
harvested. A standard plaque assay was used to determine 
the virus titer (Pharmingen, laboratory manual) prior to 
infection of SF9 cells on a quantitative scale. 
2.4. Culture and infection of SF9 cells 
SF9 cells were grown at 27°C in TC-100 insect medium 
(Gibco BRL) supplemented with 10% fetal calf serum, 2 
mM glutamin (Gibco BRL), 100 U/ml  penicillin 
(Seromed), 100 U/ml streptomycin (Seromed). For the 
production of recombinant annexin II derivatives, SF9 
cells were propagated in 800 ml flasks (Falcon) as adher- 
ent cells with 40 ml of TC-100 medium. When the density 
of the cells reached 60% confluence, the cells were in- 
fected with recombinant baculoviruses at multiplicities of 
1-2 viruses per cell. 40 hours post infection, the cells were 
harvested and used for the isolation of recombinant an- 
nexin II. 
2.5. Purification of recombinant annexin H from SF9 cells 
Infected SF9 cells expressing recombinant annexin II 
were scraped into 10 ml phosphate-buffered saline using a 
rubber policeman and harvested by low-speed centrifuga- 
tion (1200 rpm, 15 min, 4°C). The cell pellet was resus- 
pended in 5 ml buffer A (50 mM imidazole-HC1, pH 7.5, 
250 mM NaC1, 2 mM DTT, 0.2 mM PMSF, 10 /zg/ml 
aprotinin, 1 /xg/ml pepstatin, 10 /xM L-3-trans- 
carboxyoxiran-2-carbonyl-L-leucyl-agmantin (E-64, 
Biomol)) and cells were lysed by sonication for 2 × 20 sec 
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using a Branson sonifier at 30% power. The homogenate 
was adjusted to 5 mM CaC12 and then centrifuged at 
10000 rpm for 30 min at 4°C in a SS34 rotor (Sorvall). 
The pellet was resuspended in 1 ml buffer A containing 10 
mM EGTA. This step led to a complete solubilization of 
annexin II which was associated with the pelleted mem- 
branes in a Ca2+-dependent manner. The EGTA extract 
was centrifuged at 55 000 rpm for 30 min at 4°C in a 
TLAI00.3 rotor (Beckman) and the resulting supernatant 
was dialyzed against buffer B (25 mM Tris-HC1, pH 7.5, 
100 mM NaCI, 3 mM MgC12, 1 mM Dq'T, 1 mM NAN3). 
To achieve additional purification of the recombinant pro- 
tein it was dialyzed against buffer C (25 mM sodium 
acetate, pH 5.6, 1 mM DTT, 1 mM NaN 3) and then 
applied on a Mono S cation--exchange column. The column 
was developed with a linear salt gradient (0-0.5 M NaC1 
in buffer C) and annexin II eluted at approx. 250 mM 
NaC1. All annexin II derivatives were purified following 
the same procedure and could be stored at 4°C for several 
weeks. 
2.6. p l l  binding to immobilized annexin H (ligand blot- 
ting) 
SDS sample buffer and analyzed together with the super- 
natant by SDS-PAGE and ligand blotting. 
2.8. Mixed micelle and phosphatidylserine v sicle prepara- 
tion 
For micelle preparation, 200 /xl dioleoylglycerophos- 
phoserine (10 mg/ml in chloroform/methanol (90:10), 
kindly provided by Dr. H. Eibl, Max Planck Institute for 
Biophysical Chemistry, Gtittingen, Germany) were mixed 
with 4/~1 PMA (phorbol 12-myristate 13-acetate, 1 mg/ml 
in ethanol; Sigma), dried under nitrogen and then dissolved 
in 800 /xl of a buffer containing 25 mM Hepes (pH 7.4), 
and 1.5% Triton X-100 by vortexing for 2 min. 
Liposomes were prepared by mixing 200 /~1 dioleoyl- 
glycerophosphoserine (see above) with 10 /xl cholesterol 
(10 mg/ml in chloroform). The material was dried under 
nitrogen, resuspended in a buffer containing 25 mM Tris- 
HC1, pH 7.5, 100 mM NaC1 and then sonicated 3-times for 
20 sec at 30% power (Branson sonifier). Mixed micelles 
and liposomes were prepared freshly before use. 
2.9. Phosphorylation of annexin H 
1 /zg purified annexin II (wild-type or serine mutant 
derivatives) was subjected to SDS-PAGE [30] and blotted 
onto nitrocellulose membrane [31]. The membrane was 
blocked using 3% bovine serum albumin (BSA) in TBS-T 
(20 mM Tris-HC1, pH 7.4, 150 mM NaC1, 0.2% Tween 
20) and then incubated in a solution containing porcine 
pl 1 (2 /zg/ml in 3% BSA/TBS-T) for 60 min at 37°C. 
After extensive washing with TBS-T, the membrane was 
incubated for 60 min at 37°C with the monoclonal nti-pl 1 
antibody H21 [32] used at 0.3/xg/ml in 3% BSA/TBS-T. 
Bound antibody was vismdized using peroxidase conju- 
gated rabbit anti-mouse antibodies (diluted 1:6000, Dako) 
and the ECL chemoluminescence system (Amersham). 
2.7. Immunoprecipitation f the annexin H-pl l complex 
Phosphorylation f 4/zg recombinant annexin II (wild- 
type or serine mutants expressed in SF9 cells) was carried 
out for 30 min at 30°C in 50 ~1 buffer containing 25 mM 
Hepes (pH 7.4), 5 /xl mixed micelles, 5 mM MgCI z, 0.75 
mM CaCI 2, 1.2 mM fl-mercaptoethanol, and 50 ng fl-PKC 
(kindly provided by Dr. Ph. Bastians, Max Planck Institute 
for Biophysical Chemistry, G6ttingen, Germany). The re- 
action was initiated by the addition of 2.5 nmol [ 3/- 32 P]ATP 
with a specific activity of 2 /xCi/nmol. Phosphorylation 
was stopped by chloroform/methanol precipitation of the 
proteins [33], which were then analyzed by SDS-PAGE 
[30]. The SDS-polyacrylamide gels were stained with 
Coomassie brilliant blue and dried onto Whatman 3MM 
paper. Phosphorylated proteins were detected by auto- 
radiography using Kodak Xomat AR films (Kodak). 
Immunoprecipitation f reconstituted annexin II-pll 
complexes was carried out using the monoclonal anti-pl 1 
antibody H21 [32] coupled to sheep-anti-mouse IgG-con- 
jugated dynabeads (Dynal). For complex formation 3 /zg 
annexin II was mixed with 1.3 p,g pl 1 and incubated for 
30 min at room temperature. Subsequently, 50 /zl dyn- 
abeads containing 1.5/xg bound H21 IgGs were added and 
the mixture was incubated for 30 min at room temperature. 
Using a magnetic device the beads were then separated 
from the unbound protein fraction and washed two times 
with TBS-T-B (TBS-T plus 0.02% BSA) followed by 
TBS-T-B containing 0.5 M NaC1. Unbound proteins were 
recovered from the first supernatant, precipitated with 
chloroform/methanol [33] and resuspended in 15 /~1 SDS 
sample buffer [30]. The beads, representing the fraction of 
pl 1-bound annexin II, were resuspended directly in 15 /xl 
3. Results 
3.1. Expression of mutant annexin H derivatives in bac- 
ulovirus-infected insect cells 
Limited proteolysis of PKC phosphorylated annexin II 
had revealed that the serine residue whose phosphorylation 
interferes with pl 1 binding is located within the N-termi- 
nal 29 amino acids of annexin II [13]. This sequence 
harbours five serines at positions 1, 11, 17, 21, and 25 
which theoretically could serve as phosphate acceptors 
(Fig. 1). One of these, Ser-25, represents the previously 
mapped PKC site whose phosphorylation does not affect 
the annexin II-pll complex formation [12,13]. A second 
one, the N-terminally acetylated Ser-1, is highly unlikely 
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to serve as a substrate for PKC since phosphorylation f
such N-terminal serines has not been reported previously 
(for review see [34]). This leaves the serines at positions 
11, 17, and 21 as candidate residues representing the 
second PKC site functionally distinct from Ser-25. 
To distinguish between the different serines and to map 
the second PKC site we chose a mutagenesis approach. 
One, two, or three serine residues in the N-terminal do- 
main were replaced by alanine resulting in cDNAs encod- 
ing a SI1A, a $21/25A and a SI 1/21/25A derivative of 
annexin II (Fig. 1). These mutations were selected to 
unambiguously identify the acceptor site after PKC phos- 
phorylation of the expressed mutant proteins. If Ser-21 
were the second PKC site (in addition to Ser-25) phospho- 
rylation of the $21/25A mutant should be completely 
abolished. Phosphorylation of this mutant but not the 
S 11/21/25A derivative would be expected to occur in the 
case of Set-11 being the second site. Finally, Ser-17 would 
have been identified as second PKC-site if both, $21/25A 
and S l l /21 /25A,  would continue to serve as PKC sub- 
strates. The S l lA  mutant was included as a positive 
control since it contained an unaltered Ser-25 known to 
represent a site for PKC phosphorylation [12,13]. 
Correct N-terminal processing of annexin II - i.e., 
acetylation of the N-terminal serine residue - is a pre- 
requisite for pl 1 binding and is likely to effect he folding 
of the N-terminal domain (for review see [35]). Since 
N-terminal acetylation could also affect phosphorylation, 
we chose an eucaryotic expression system known to yield 
a faithfully processed N-terminal end for generating the 
serine mutant derivatives of annexin II. The cDNAs encod- 
ing wild-type annexin II or the Sl lA, $21/25A, and 
S l l /21 /25A mutants, respectively, were cloned into the 
baculovirus transfer vector pVL1393 and the resulting 
constructs were used to transfect SF9 insect cells. Analysis 
of the total protein fraction of the infected insect cells by 
SDS-PAGE reveals that the recombinant proteins are effi- 
ciently expressed (an example is shown for wild-type 
annexin II in Fig. 2). All annexin II derivatives were 
purified from the appropriately infected SF9 cells by a 
combination of a Ca 2 +-dependent protein fractionation and 
ion-exchange chromatography. This protocol yielded 200 
/zg of essentially pure protein (> 95% pure as judged by 
SDS-PAGE) from 5 × 10 7 SF9 ceils grown in a 800 ml 
WT AG-STVHE I LCKL  SLEGDHST PP  SAYGSVKAY-  [ core  
S11A . . . . . . . . . .  A . . . . . . . . . . . . . . . . . . .  
S21Z25A . . . . . . . . . . . . . . . . . . . .  A -  - -A  . . . . .  
S11f21/25A . . . . . . . . . .  A . . . . . . . . .  A -  - -A  . . . . .  
Fig. 1. Sequence of the N-terminal 29 amino-acid residues of annexin II. 
The sequence of wild-type human annexin II [25] is compared to that of 
the serine mutants generated here. In these mutant derivatives putative 
PKC phosphorylation sites (marked by asterisks) were inactivated by 
alanine-to-serine substitutions. Dashes indicate that the mutant sequences 
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Fig. 2. Purification of recombinant wild-type annexin II from SF9 cells. 
Proteins present in the different fractions of the purification scheme were 
separated by 12.5% SDS-PAGE and then stained with Coomassie brilliant 
blue. Lane 2 shows the total cellular lysate of insect cells which were 
infected for 40 h with recombinant baculoviruses containing the wild-type 
annexin lI cDNA insert under control of the polyhedrin promoter. After 
addition of Ca 2+ the lysate was centrifuged to separate the annexin II 
containing pellet fraction (lane 4) from soluble components (lane 3). 
Annexin II was specifically released from the pellet by adding a Ca 2+ 
chelating agent (lane 5). Lane 6 shows the protein after a final purifica- 
tion step on Mono S. Marker proteins of the relative molecular masses 
(× 10 -3) indicated are given in lane 1. 
flask. An example showing an analysis of the different 
purification steps by SDS-PAGE is given in Fig. 2 for 
wild-type annexin II. The isolation of the recombinant 
annexin II derivatives was also verified by immunoblotting 
of the purified proteins with a polyclonal antibody directed 
against annexin II (not shown). 
3.2. Biochemical characterization of the recombinant an- 
nexin H derivatives expressed in SF9 cells 
The annexin II derivatives purified from infected SF9 
cells (WT, SIlA, $21/25A, and S l l /21 /25A,  respec- 
tively) were first subjected to phospholipid liposome pel- 
leting. In this assay annexins are typically pelleted together 
with the liposomes in a Ca2+-dependent manner (for re- 
view see [2]). This property is shared by all annexin II 
derivatives expressed in SF9 cells and the results are 
indistinguishable from those obtained for authentic an- 
nexin II purified from porcine intestine (not shown). To 
analyze the folding of the N-terminal domain relative to 
the protein core we then subjected the recombinant an- 
nexin II derivatives to immunoblotting with the mono- 
clonal antibody H28 [32]. This antibody recognizes a 
discontinuous epitope which involves Lys-27 of the N- 
terminal domain and Arg-62 and Arg-67 of the first an- 
nexin repeat [36]. All annexin II derivatives expressed in 
SF9 cells showed the same reactivity towards the H28 
antibody as authentic porcine annexin II indicating that the 
close proximity of the N-terminal domain and the first 
annexin repeat of the protein core is not affected in the 
region of the epitope (not shown). 
Complex formation of the recombinant proteins with 
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p l l  was analyzed by employing a ligand blotting assay. 
Here, we exploited the ability of immobilized annexin II to 
bind pl 1 [37]. The annexin H derivatives expressed in SF9 
cells as well as authentic annexin II isolated from porcine 
intestine (as positive contrel) and a bacterially expressed 
annexin II containing an altered N-terminal end [38] (as 
negative control) were subjected to SDS-PAGE, trans- 
ferred to nitrocellulose, and then incubated with a solution 
containing p l l  purified from porcine intestine. Subse- 
quently, p l l  binding to the immobilized proteins was 
monitored by staining with a monoclonal antibody directed 
against pl 1. Fig. 3A shows that all annexin II derivatives 
expressed in SF9 cells bind p l l  with similar efficiency 
thus demonstrating that all possess a correctly processed 
N-terminal end. In contrast, the bacterially expressed pro- 
tein, which contains an additional six amino acids fused to 
the N-terminal domain and which is not acetylated at its 
N-terminal end [38], fails to interact with pl 1. 
A B 
1 2 3 4 5  1 2 34  
anx II 
anx,  - - .  ~__, ~ Koa 
. . . . .  ....... o . -  
Fig. 3. Interaction of the recombinant annexin II derivatives with pl ] as 
revealed by ligand blotting (A) and immunoprecipitation (B). Panel A 
shows a ligand blotting assay. 1 /~g annexin II purified from E. coil cells 
expressing human annexin II [38] (lane 1), purified from porcine intestine 
(lane 2), and purified from SE9 cells expressing wild-type (lane 3), S1 IA  
(lane 4), and $21/25A annexin II (lane 5), respectively, was subjected to 
SDS-PAGE and then transferred to nitrocellulose. The membrane was 
incubated in a solution containing porcine pl 1 and annexin II-bound pl 1 
was subsequently visualized by immunoblotting. Note that pl 1 only binds 
to annexin II derivatives containi~ag a correctly processed - -  i.e. acety- 
lated, N-terminal end. In contrast the bacterially expressed protein fails to 
interact with p 11 and only shows background labelling, lmmunoprecipita- 
tion of a complex reconstituted from pl 1 and recombinant annexin II is 
shown in B. Wild-type annexin I]( expressed in SF9 cells was incubated 
with pl 1 and the reconstituted annexin II-pl 1 complex was immunopre- 
cipitated using the monoclonal anti-pl I antibody H21 bound to magnetic 
beads. The non-precipitated fraction (lanes 1 and 2) and the immunopre- 
cipitated material (lanes 3, 4) were subjected to SDS-PAGE and immuno- 
blotting using the monoclonal anti-annexin II antibody H28 [32]. This 
antibody recognizes a discontinuo,as epitope which involves Lys-27 of the 
N-terminal domain and Arg-62 and Arg-67 of the first annexin repeat [36] 
and thus recognizes not only intact annexin II (36 kDa) but also a 
N-terminally truncated erivative., of 33 kDa generated by proteolysis 
which occurred upon longer storage. Note that this proteolysed protein 
remains in the superuatant due to a loss of the pl 1 binding site compris- 
ing residues 1-14. Intact recombinant annexin II, on the other hand, is 
co-immunoprecipitated with pl 1 (lane 3). Lanes 2 and 4 show controls in 
which the precipitation was carried out without adding pl l .  Arrows 
indicate heavy and light chains of the H21 antibodies which were used 
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Fig. 4. Phosphorylation f the recombinant annexin II derivatives by 
PKC. Human annexin II and the mutant derivatives carrying amino-acid 
substitutions in putative serine phosphorylation sites of the N-terminal 
domain (see Fig. 1 for details) were expressed in baculovirus-infected 
SF9 cells and purified as described (see Fig. 2 for details). Identical 
amounts of the purified proteins were subjected toa PKC phosphoryla- 
tion reaction i  the presence (lanes 1, 3, 5, and 7) or absence (lanes 2, 4, 
6, and 8) of phospholipid micelles and then analyzed by SDS-PAGE and 
autoradiography. Note that he annexin II derivatives S11A (lane 3) and 
$21/25A (lane 5) are phosphorylated to a level of approx. 50% as 
compared tothat of wild-type annexin II. This indicates the loss of one of 
the two phosphorylation sites located in the N-terminal domain. 
S11/21/25A fails to serve as a substrate for PKC indicating that Ser-17 
is not phosphorylated (lane 7). 
The interaction between p l 1 and annexin II expressed 
in SF9 cells was also analyzed by co-immunoprecipitation. 
Therefore, the purified annexin II derivatives were incu- 
bated with an equimolar amount of porcine p l l  and the 
mixture was then subjected to immunoprecipitation with a 
monoclonal anti-pl 1 antibody attached to magnetic beads. 
All SF9-expressed erivatives are precipitated with the 
beads in a strictly pl l-dependent manner indicating that 
p 11 binding and reconstitution of the annexin II-p 11 com- 
plex had occurred (a representative example, in this case 
for wild-type annexin II, is shown in Fig. 3B). Thus, by all 
criteria analyzed recombinant annexin II expressed in SF9 
insect cells displays the same biochemical properties as the 
authentic protein purified from mammalian cells. More- 
over, the serine mutants generated here (S11A, $21/25A,  
and S11/21 /25A annexin II) are biochemically indistin- 
guishable from wild-type annexin II. 
3.3. Ser-11 is the second PKC phosphorylation site in the 
N-terminal domain of annexin H 
The annexin II proteins purified from SF9 insect cells 
(WT, S l lA ,  $21/25A,  and S l l /21 /25A annexin II) 
were subjected to a standard PKC phosphorylation reaction 
using conditions employed previously to describe the exis- 
tence of two functionally distinct PKC sites [13]. Fig. 4 
shows the combined results of these phosphorylation reac- 
tions. When compared to WT annexin II only approx. 50% 
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of the label is incorporated in the S l lA  and $21/25A 
mutant proteins indicative of an inactivation of one of the 
two phosphorylation sites in each of the two mutants. This 
must be the known Ser-25 in the $21/25A derivative and 
is likely to be Ser-ll in the SI1A mutant. Finally, the 
S 11/21/25A mutant protein, which only contains a serine 
residue at position 17, fails to serve as a substrate for PKC 
(Fig. 4). Since $21/25A annexin II - i.e., a mutant 
containing the only serine residues of the N-terminal do- 
main at positions l l and 17 - continues to become 
phosphorylated and since Ser-17 can be excluded as a 
target for PKC (the $11/21/25A derivative is not phos- 
phorylated), our combined results unambiguously identify 
Ser-ll as the second serine phosphorylation site. As ex- 
pected for PKC catalyzed reactions all phosphorylations 
required the presence of phospholipid micelles as a cofac- 
tor for the enzyme (Fig. 4, compare lanes 1, 3, 5, and 7 to 
lanes 2, 4, 6, and 8, respectively). 
4. Discussion 
Annexin II, a member of the annexin family which is 
subject to a number of post-translational modifications 
including phosphorylation by PKC, has been implicated in 
membrane-related events along the endocytic and the regu- 
lated secretory pathway (for review see [1,4]). In particu- 
lar, later steps in the Ca2+-regulated secretion of catechol- 
amines in chromaffin cells and the peripheral positioning 
of early endosomes in polarized epithelial cells appear to 
be affected by annexin II [19,24,39]. It has been discussed 
that annexin II plays a structural role in these processes by 
organizing membranes, by providing a physical ink be- 
tween membrane surfaces (e.g., the chromaffin granule and 
the plasma membrane) and/or by linking membranes to 
the associated cytoskeleton. Such a bridging activity would 
depend on the formation of the annexin II-pll hetero- 
tetramer which contains two annexin II cores and thus two 
binding domains for phospholipids and/or cytoskeletal 
elements. In this scenario PKC catalyzed phosphorylation 
at Ser-11 of the annexin II chain would be of critical 
regulatory importance. It would interfere with the annexin 
II-pl 1 interaction leading to an accumulation of annexin II 
monomers no longer capable of providing membrane- 
membrane and/or membrane-cytoskeleton linkages. 
Ser-ll of annexin II is part of the p l l  binding region 
which comprises residues 1 to 14 [16]. However, it is most 
likely not directly involved in establishing protein-protein 
interactions, ince the hydrophobic side chains at position 
3, 6, 7, and 10 represent the major contact sites for pl 1 
[40]. These lie on the hydrophobic side of an amphiphatic 
c~-helix formed by the N-terminal 14 residues of annexin 
II. In a helical wheel projection of this sequence Ser-11 is 
located at the border between the hydrophobic and the 
hydrophilic side of the helix [16]. This spatial relationship 
would explain that the alanine for serine replacement in
our S l lA  mutant has no effect on p l l  binding (Fig. 3), 
whereas the introduction of the negatively charged phos- 
phate group in phosphorylated annexin II inhibits p l 1 
binding. The latter is also illustrated in an analysis of the 
p 11 interaction with synthetic peptides comprising residues 
1 to 14 of annexin II (with an acetylated N-terminal serine; 
Acl-14) or mutations of this sequence. While wild-type 
Acl -14 is capable of binding p l l  with high affinity and 
specificity, a mutant peptide containing a single aspartic 
acid for serine replacement at position 11 shows a markedly 
reduced affinity [40]. Thus, the introduction of a side chain 
with a negative charge at position 11 (through phosphory- 
lation or amino-acid replacement) probably plays an im- 
portant role in reducing within the N-terminal domain of 
annexin II the affinity for p 11. 
While phosphorylation at Ser-11 could directly regulate 
the annexin II-p 11 interaction, the second PKC phosphory- 
lation site present in the N-terminal domain of annexin II 
(Ser-25) is also accessible in the annexin II-pll complex 
and phosphate incorporation at this site does not interfere 
with p l l  binding [13]. However, Ser-25 phosphorylation 
by PKC also regulates biochemical and most likely func- 
tional properties of annexin II. In a lipid vesicle aggrega- 
tion assay, PKC phosphorylated annexin II2pl 12 shows a 
markedly increased Ca 2+ requirement for the aggregation 
activity when compared to the non-phosphorylated coun- 
terpart [18]. Since Ser-ll is shielded by the bound p l l  in 
the preformed annexin II-pl 1 complex [13] PKC phospho- 
rylation occurred exclusively on Ser-25 in these experi- 
ments. Thus, phosphate incorporation at Ser-25 can affect 
a property requiring the lipid binding activity of the an- 
nexin II core probably due to a close spatial proximity of 
Ser-25 and the first repeat of the annexin core [36]. An 
effect of Ser-25 phosphorylation is also observed when the 
possible participation of annexin II in CaE+-induced secre- 
tion is analyzed in permeabilized chromaffin cells. Here, 
the annexin II-pl 1 complex is able to partially restore the 
secretory activity when added to digitonin permeabilized 
cells, however, only as long as the cells contain cytosolic 
PKC activity. Moreover, annexin IIepl 12 pre-phosphory- 
lated by PKC can stimulate secretion in PKC-depleted 
cells indicating that Ser-25 phosphorylation is a pre- 
requisite for a function of the annexin II-pl I complex in 
CaE+-evoked exocytosis [19]. It is not clear how this 
relates to the inhibition of vesicle aggregation observed 
after PKC phosphorylation at Ser-25 (see above), in partic- 
ular, since annexin II-pl 1 is thought o function in chro- 
maffin granule exocytosis by providing intergranular 
and/or granule-plasma membrane links ([23]; for review 
see [ 1 ]). 
The combined results indicate that activation of protein 
kinase C in cells expressing annexin II and p l l  would 
have two consequences with respect o the intracellular 
regulation of annexin II activities. First, annexin II-pll 
complexes already formed would be phosphorylated at
Ser-25 of the annexin II chains thereby activating a possi- 
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ble function of the complex in Ca2÷-regulated secretion. 
Second, monomeric annexin II would also be phosphory- 
lated at Ser - l l .  This event would inhibit complex forma- 
tion with p l l  and thus interfere with a proper incorpora- 
tion of annexin II in the cortical region of the cell. The 
latter modif ication would then affect all cortical activities 
of annexin II, in particular at later times exceeding the half 
life of preformed annexin I I -p l  1 complexes. 
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